Medtronic Announces Breakthrough in Chronic Pain Treatment with Positive Clinical Data on Closed-Loop Spinal Cord Stimulation
Jan 20, 2024 00:01
CST Updated
00:02
Medtronic
Chronic Disease Medical Device and Therapy Developer
The study achieved its primary goal, with 89% of subjects reporting that compared to the open-loop SCS system,Significantly reduced incidence of overstimulation(n=28; p<0.001). In addition, 86% of subjects reported a preference for the closed-loop SCS system during the one-month blinded trial period. The study met the secondary endpoint, with 86% of subjects (n=51) indicatingOverall, back and leg pain was reduced by 50% or more after three months.。 Three months later, 100% of the subjects expressed satisfaction with the closed-loop SCS treatment; Three months later, more than 80% of the subjects who received SCS treatment said they were not worried about pain or side effects of the treatment and could achieve their self-defined daily activity goals. Three months later, the group receiving closed-loop SCS showed clinically significant improvements in pain, physical function, and quality of life. The trial did not include a withdrawal plan, however35% of subjects (n=37) who initially took opioid medications reduced/stopped use after three months.The milligram equivalent of morphine decreased from 73.5 to 54.0.
DTM™ SCS therapy showed a better positive response to treatment at 12, 18, and 24 months in patients with chronic low back pain compared to CMM. 
Patients using DTM™ SCS therapy at 24 months,Chronic Low Back Pain Reduced by 77%； Using DTM™ SCS TherapyUp to 93% of patients with leg pain responded positively to the treatment., In addition, among these patients,Reduction in leg pain ≥50%； According to the Oswestry Disability Index (ODI) assessment, patients using DTM™ SCS therapy experienced an average reduction of >26 points in the ODI score after 24 months. After 24 months, 95% of patients were satisfied or very satisfied with DTM™ SCS therapy.
